Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease

Journal of Comparative Neurology

Volumn 437, Issue 3, 2001, Pages 296-307

  Chu, Yaping ^a   Cochran, Elizabeth J ^a   Bennett, David A ^a   Mufson, Elliott J ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Dementia; Gene; Mild cognitive impairment; Nucleus basalis; trkA

Indexed keywords

APOLIPOPROTEIN E; MESSENGER RNA; NERVE GROWTH FACTOR RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN NERVE CELL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MEMORY; OLIVARY NUCLEUS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BASAL NUCLEUS OF MEYNERT; CELL SIZE; DISABILITY EVALUATION; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEURONS; NEUROPSYCHOLOGICAL TESTS; RECEPTOR, TRKA; RNA, MESSENGER;

EID: 0035959515     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/cne.1284     Document Type: Article

References (63)

1. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease
2. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease
3. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy
4. Around the WORLD backward: An algorithm for scoring the MMSE WORLD item
5. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale
6. Dimensionality of parkinsonian signs in aging and Alzheimer's disease
7. Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease
8. Neuropathological staging of Alzheimer-related changes
9. Severe panencephalic Pick's disease with Alzheimer's disease-like neuropil threads and synaptophysin immunoreactivity
10. Reduced transport of [125I] nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats
11. Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease
12. Cholinergic markers in elderly patients with early signs of Alzheimer disease
13. Analysis of choline acetyltransferase activity in cortex of individuals with mild cognitive impairment and Alzheimer's disease
14. Questionable dementia: Clinical course and predictors of outcome
15. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons
16. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by NGF
17. Mild cognitive impairment in the elderly: Predictors of dementia
18. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician
19. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease
20. Effects of estrogen and fimbria/fornix transection on p75NGFR and ChAT expression in the medial septum and diagonal band of Broca
21. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease
22. Interrater reliability of the NIH stroke scale
23. Nerve growth factor and Alzheimer's disease
24. Nerve growth factor levels and choline acetyltransferase activity in the brain of aged rats with spatial memory impairments
25. The time course of nerve growth factor content in different neuropsychiatric diseases - A unifying hypothesis
26. Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease
27. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease
28. Nerve growth factor mediates signal transduction through trk homodimer receptors
29. The cholinergic system in Alzheimer's disease
30. Signal transduction by the neurotrophin receptors
31. The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor
32. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment
33. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease
34. Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrain
35. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
36. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain. Observation based on the distribution of acetylcholinesterase and choline acetyltransferase
37. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia Innominata), and hypothalamus in the Rhesus monkey
38. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
39. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease
40. Nerve growth factor and its receptors in the primate forebrain: Alteration in Alzheimer's disease and potential use in experimental therapeutics
41. Nerve growth factor in Alzheimer's disease
42. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain
43. Nerve growth factor in Alzheimer's disease: Defective retrograde transport to nucleus basalis
44. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease
45. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease
46. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment
47. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease
48. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
49. Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician's diagnosis
50. Neurotrophin dependence mediated by p75NTR: Contrast between rescue by BDNF and NGF
51. An NGF-TrkA-mediated retrograde signal to transcription factor CREB in sympathetic neurons
52. Apolipoprotein E genotyping as a diagnostic adjunct for Alzheimer's disease
53. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy
54. Very mild senile dementia of the Alzheimer type. I. Clinical assessment
55. Nerve growth factor in Alzheimer's disease: Increased levels throughout the brain coupled with declines in nucleus basalis
56. Human trks: Molecular cloning, tissue distribution, and expression of extracellular domain immunoadhesins
57. Brain acetylcholinesterase activity in Alzheimer disease measured by positron emission tomography
58. TrkA-immunoreactive profiles in the central nervous system: Colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin
59. Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: An in situ hybridization study
60. Proceedings of the meeting of the American Society for Neural Transplantation and Repair (ASNTR)
61. Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition